Pimavanserin is an atypical antipsychotic primarily used in the treatment of Parkinson's disease psychosis. It functions as a selective inverse agonist of the 5-HT2A serotonin receptor, which distinguishes it from traditional antipsychotics that often block dopamine receptors. This selectivity is significant as it minimizes the risk of extrapyramidal side effects commonly associated with dopamine antagonism. Pimavanserin is characterized by its unique chemical structure, which includes a complex bicyclic framework. It is administered orally and has a relatively long half-life, allowing for once-daily dosing. The drug is metabolized primarily by the liver, involving cytochrome P450 enzymes, and it exhibits a low potential for drug-drug interactions. Clinical studies have demonstrated its efficacy in reducing hallucinations and delusions in patients with Parkinson's disease, making it a valuable therapeutic option in managing psychotic symptoms without exacerbating motor symptoms. Overall, Pimavanserin represents a novel approach in the pharmacological management of psychosis in neurodegenerative disorders.

Pimavanserin

932724-63-5: Pimavanserin is an atypical antipsychotic primarily used in the treatment of Parkinson's disease psychosis. It functions as a selective inverse agonist of the 5-HT2A serotonin receptor, which distinguishes it from traditional antipsychotics that often block dopamine receptors. This selectivity is significant as it minimizes the risk of extrapyramidal side effects commonly associated with dopamine antagonism. Pimavanserin is characterized by its unique chemical structure, which includes a complex bicyclic framework. It is administered orally and has a relatively long half-life, allowing for once-daily dosing. The drug is metabolized primarily by the liver, involving cytochrome P450 enzymes, and it exhibits a low potential for drug-drug interactions. Clinical studies have demonstrated its efficacy in reducing hallucinations and delusions in patients with Parkinson's disease, making it a valuable therapeutic option in managing psychotic symptoms without exacerbating motor symptoms. Overall, Pimavanserin represents a novel approach in the pharmacological management of psychosis in neurodegenerative disorders.

CAS 932724-63-5

Pimavanserin

Pimavanserin Impurity 16

Ref: 4Z-P-281019

Tri(4-fluorobenzyl)amine

Ref: TR-T781565

Pimavanserin Impurity 16

Ref: ST-EA-CP-P112018